Centene, WellCare $17.3B merger clears regulatory requirements

Centene has passed all regulatory hurdles to seal the deal on a merger with WellCare Health Plans worth $17.3 billion.

Centene, a Fortune 100 company, is a multinational healthcare business that provides health plans and services. Tampa-based WellCare offers managed care plans through Medicaid, Medicare Advantage, Medicare Prescription Drug Plans and the individual marketplace. WellCare acquired the Medicare Part D prescription drug plan of Aetna in 2018 as part of Aetna’s $69 billion merger with CVS Health.

“We are pleased to achieve this milestone and look forward to closing our acquisition of WellCare and providing more members and communities access to high-quality healthcare," Michael F. Neidorff, Centene's chairman, president and CEO, said in a statement. "We also look forward to building on our relationships with providers and government partners through the combined company's wide range of affordable health solutions. We have been working diligently on the integration plans to bring our organizations together so that it is seamless for members, providers and employees of both companies."

The merger was approved by shareholders of both Centene and WellCare back in June 2019. All regulatory requirements have been met under the merger agreement as well as approval from the Department of Justice.

As part of the deal, WellCare will divest its Medicaid and Medicare Advantage Plans in Missouri and Medicaid plan in Nebraska. Centene will divest its Medicaid and Medicare Advantage plans in Illinois. The divestitures will occur on or about January 23, 2020, according to the announcement.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.